Therapeutic Markets

Radiation Therapy-Induced Fibrosis

According to the American Cancer Society (Cancer Facts & Figures 2008), there will be 1.4 million new cases of cancer in the U.S. alone. Also, the "National Cancer Institute estimates that approximately 10.8 million Americans with a history of cancer were alive in January 2004," of which many are still undergoing treatment.

It is estimated that as many as 50% of all cancer patients will undergo radiation therapy. Of those, approximately 40% will suffer some form of radiation therapy-induced fibrosis (RTIF). Because ALT-0701 will be effective as a preventive treatment, as well as a therapy for fibrosis, AltruGen intends to treat all radiation tharapy patients initially. Based on an estimated treatment cost of $2,000 to $2,500 per patient, BioCure Pharma believes this to be a $1.4 to $3.5 billion market per year for the U.S. alone.

Asthma and COPD

In 2006, the American Lung Association estimated that 22.9 million Americans (6.8 million children under 18) have asthma. "Of these, 12.4 million Americans (4.1 million children under 18) had an asthma attack."

Although evidence suggests that prevalance rates and asthma deaths have begun to plateau or even decrease, in 2005 alone, 3,884 deaths were attributed to asthma-related complications. Annually, the direct cost of asthma is estimated to be $14.7 billion ($6.2 billion

in prescription drugs) and indirect cost at an additional $5 billion. InflammoGen intends to treat asthmatics with BCP-1071 as a preventive measure, as well as to develop a fast-acting drug for asthma attacks. BioCure Pharma estimates the market potiential of BCP-1071 to be $6 to $7 billion per year for the U.S. alone. BioCure Pharma also intends to address many other inflammatory diseases, such as chronic obstructive pulmonary disease (COPD). Moreover, BioCure Pharma will pursue its IP through four additional patents held internationally.